Institute for Clinical Pharmacology & Safety — Bethesda, MD 20814
ICPS
Human Formulations Only

Ivermectin for Humans: Clinical Safety and Approved Uses

A focused reference on FDA-approved human-grade ivermectin formulations—oral tablets and topical preparations—covering approved indications, safety parameters, and common misconceptions.

This page covers human formulations exclusively. For animal/veterinary ivermectin, see our Veterinary Use page.
MV

Peer-Reviewed by Dr. Marcus Vance, MD, PhD

Lead Clinical Pharmacologist, Institute for Clinical Pharmacology & Safety — Board-certified in Clinical Pharmacology & Toxicology. Reviewed for scientific accuracy against current FDA label documentation, WHO technical monographs, and peer-reviewed literature.

Peer Reviewed

Human-Grade Ivermectin: What That Term Actually Means

"Human-grade" is not a marketing phrase—it is a regulatory and manufacturing classification. Ivermectin products intended for human consumption are manufactured under FDA Current Good Manufacturing Practice (cGMP) standards applicable to human drugs (21 CFR Parts 210/211). These standards govern raw material purity, excipient quality, manufacturing process controls, sterility testing (where applicable), and shelf-life determination. They are considerably more stringent than the analogous standards applied to veterinary pharmaceutical manufacturing.

Human-grade oral ivermectin is formulated specifically for human pharmacokinetics: tablet strength (3 mg), inactive ingredient profiles appropriate for human consumption, and dissolution characteristics validated against human pharmacokinetic endpoints. This is not a trivial distinction. The active molecule—ivermectin—is chemically identical across human and veterinary formulations. But the concentration, excipient composition, and manufacturing controls differ substantially. That is why the two categories must never be conflated.

FDA-Approved Human Formulations

Three distinct FDA-approved ivermectin product categories exist for human use in the United States:

1. Oral Tablets — Stromectol and Generic Equivalents (3 mg)

The 3 mg oral tablet is the standard systemic human formulation. Approved for intestinal strongyloidiasis and onchocerciasis, the tablet achieves measurable plasma concentrations and distributes systemically to target tissue. A prescription is required. Dosing is weight-based. These are the only oral ivermectin products approved by the FDA for human parasitic indications.

2. Topical Cream — Soolantra 1% (Ivermectin Cream)

Soolantra (ivermectin 1% cream) received FDA approval in 2014 for the treatment of inflammatory lesions of rosacea—specifically the papulopustular variant. The mechanism underlying its anti-rosacea effect is not fully elucidated; hypotheses include anti-inflammatory activity and activity against Demodex folliculorum, a microscopic mite with a proposed role in rosacea pathogenesis. Systemic absorption from topical application to intact facial skin is minimal, making the systemic pharmacokinetic and safety considerations of oral ivermectin largely inapplicable to this formulation.

Soolantra requires a prescription. It is indicated for once-daily facial application and has demonstrated superiority to placebo in multiple Phase 3 clinical trials, with a favorable tolerability profile.

3. Topical Lotion — Sklice 0.5% (Ivermectin Lotion)

Sklice (ivermectin 0.5% lotion) carries FDA approval for the topical treatment of head lice (Pediculus humanus capitis) in patients aged 6 months and older. A single application is typically sufficient, applied to dry hair and scalp and rinsed after 10 minutes. Systemic absorption is negligible. This product is available without a prescription in certain over-the-counter formulations, making it the only ivermectin product for humans legally obtainable without a prescriber's involvement in the United States.

Safety Profile of Human Ivermectin: Evidence at Scale

Oral ivermectin's human safety record is among the most extensive in modern antiparasitic pharmacology. The Mectizan Donation Program—a collaboration between Merck and global health institutions to combat onchocerciasis—has administered over 4 billion doses since 1987. That is not a misprint. The adverse event signal at approved doses, drawn from this enormous real-world dataset, is predominantly mild and largely attributable to Mazzotti-type reactions (immune responses to parasite death) rather than direct drug toxicity.

Documented adverse events in clinical trials and post-marketing surveillance at approved doses include:

  • Fever, chills, and myalgia (common; typically transient)
  • Pruritus and skin rash (common; Mazzotti-related in parasitized patients)
  • Peripheral edema, facial edema (less common)
  • Dizziness, somnolence (uncommon; self-limiting)
  • Nausea, abdominal pain (uncommon)
  • Tachycardia, hypotension (rare)
  • Neurological effects (rare; associated with high doses, CNS vulnerability, or Loa loa co-infection)

Pharmacogenomic Considerations in Human Patients

The CNS safety margin for human patients depends critically on intact P-glycoprotein efflux function at the blood-brain barrier. Variants in the ABCB1 gene (encoding P-gp) affect the brain's ability to export ivermectin from CNS tissue. Patients with certain ABCB1 single-nucleotide polymorphisms may exhibit increased CNS sensitivity to ivermectin. While clinical cases attributable solely to pharmacogenomics are rare, prescribers managing patients with known CNS barrier dysfunction or those taking P-gp inhibitors should exercise heightened caution.

Clearing Up Common Misconceptions

Public confusion about ivermectin increased substantially after 2020. Several misconceptions warrant explicit correction:

  • Misconception: Ivermectin is only for animals. — False. Ivermectin has been approved for human use in the United States since 1987 and has been used to treat hundreds of millions of humans in verified medical programs.
  • Misconception: Veterinary ivermectin is equivalent to human ivermectin and can be safely self-administered. — False. Veterinary formulations differ in concentration, excipients, and manufacturing standards in ways that pose genuine safety risks to humans. This is addressed fully on our Veterinary Use page.
  • Misconception: Human ivermectin is freely available over the counter. — False. Oral ivermectin tablets require a prescription in the United States. See our OTC Status page for the regulatory basis.
  • Misconception: Ivermectin is a "Nobel Prize-winning COVID treatment." — This conflates the Nobel Prize (awarded for the discovery of the drug as an antiparasitic) with clinical utility in a different context. The FDA has not approved ivermectin for COVID-19, and current regulatory guidance does not support its use for that indication.

Contraindications and Drug Interactions

Known contraindications to oral ivermectin include hypersensitivity to the drug or any of its excipients. Caution is warranted in patients with impaired hepatic function. The drug should not be co-administered with warfarin without close INR monitoring, as ivermectin has been reported to potentiate anticoagulant effects. Strong CYP3A4 inhibitors (e.g., ketoconazole, certain azole antifungals) may increase systemic exposure. These interactions should be reviewed by the prescribing clinician in the context of the patient's full medication list.